BMY Bristol Myers Squibb Co

  1. Stocks
  2. Healthcare
  3. NYSE: BMY

Price (delayed)

$56.6

Market cap

$115.58B

P/E Ratio

15.85

Dividend/share

$2.5

EPS

$3.57

Enterprise value

$150.47B

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 52
Relative Valuation: Rel. Valuation: 79
Relative Profitability: Rel. Profitability: 93

Bristol Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, ...

Highlights
The net income has grown by 34% year-on-year and by 3.1% since the previous quarter
Bristol Myers Squibb's EPS has increased by 33% YoY and by 2.9% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.bms.com/
Peers: MRK LLY PFE NVS

Key stats

What are the main financial stats of BMY

BMY stock price

How has the Bristol Myers Squibb stock price performed over time
Intraday
3.44%
1 week
-0.54%
1 month
-1.36%
1 year
18.04%
YTD
4.93%
QTD
-6.68%

Financial performance

How have Bristol Myers Squibb's revenue and profit performed over time
Revenue
$48.48B
Gross profit
$34.16B
Operating income
$9.6B
Net income
$7.28B
Gross margin
70.5%
Net margin
15%
The operating income has surged by 57% year-on-year and by 2.9% since the previous quarter
The operating margin has surged by 55% year-on-year and by 2.1% since the previous quarter
The net income has grown by 34% year-on-year and by 3.1% since the previous quarter
BMY's net margin is up by 32% year-on-year and by 2.7% since the previous quarter

Price vs fundamentals

How does BMY's price correlate with its fundamentals

Growth

What is Bristol Myers Squibb's growth rate over time

Valuation

What is Bristol Myers Squibb stock price valuation
BMY P/E details
P/E
15.85
P/B
5.74
P/S
2.38
EV/EBIT
15.68
EV/EBITDA
11.41
EV/Sales
3.1
Bristol Myers Squibb's EPS has increased by 33% YoY and by 2.9% QoQ
The stock's price to earnings (P/E) is 8% less than its last 4 quarters average of 16.6
Bristol Myers Squibb's equity has increased by 15% YoY and by 9% from the previous quarter
BMY's P/B is 9% above its 5-year quarterly average of 5.1
The price to sales (P/S) is 15% less than the 5-year quarterly average of 2.7 but 4.5% more than the last 4 quarters average of 2.2

Efficiency

How efficient is Bristol Myers Squibb business performance
BMY's return on invested capital has surged by 66% year-on-year and by 3.3% since the previous quarter
Bristol Myers Squibb's return on sales has surged by 55% YoY and by 2.1% QoQ
Bristol Myers Squibb's ROA has increased by 36% YoY and by 5% from the previous quarter
The ROE has grown by 22% YoY

Dividends

What is BMY's dividend history
Dividend details
DPS
$2.5
Dividend yield
4.42%
Payout ratio
70%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Bristol Myers Squibb financials performed over time
BMY's total assets is 30% greater than its total liabilities
Bristol Myers Squibb's current ratio has increased by 13% from the previous quarter and by 11% YoY
The total liabilities has declined by 11% year-on-year and by 7% since the previous quarter
BMY's debt is 122% greater than its equity
The company's debt to equity fell by 22% YoY and by 9% QoQ
Bristol Myers Squibb's equity has increased by 15% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.